Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a brief audio tour around key developments in the global biopharma industry over the past week, in this podcast version of Scrip's Five Must-Know Things. 

Join us in our regular podcast covering major industry events over the past week, in this audio version of Scrip's Five Must-Know Things, this time for the business week ended 13 November 2020.

COVID-19 vaccines dominate developments this time, along with a failed deal in idiopathic pulmonary fibrosis and yet another setback in Alzheimer's disease.

 

These and other Informa Pharma Intelligence podcasts are available on SoundCloud, Apple Podcasts and TuneIn, and also as a skill on Alexa smart speakers.

Articles mentioned in this episode:

(Also see "Pfizer And BioNTech Claim COVID-19 Vaccine Success" - Scrip, 9 Nov, 2020.)

(Also see "COVID-19 Vaccine Results A Breakthrough Moment For BioNTech" - Scrip, 11 Nov, 2020.)

(Also see "Sanofi CEO Takes Not-So-Slow And Steady Approach To COVID-19 Vaccines" - Scrip, 10 Nov, 2020.)

(Also see "Boehringer, Bridge IPF Deal Collapses On Toxicity Concerns" - Scrip, 11 Nov, 2020.)

(Also see "Aducanumab Panel Pushes Back On Rosy FDA Outlook, Could Derail A Swift Approval" - Scrip, 7 Nov, 2020.)

Details of the FDA/CMS summit on 7-9 December as mentioned in the podcast can be found here.

 

Related Content

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel